Regen BioPharma, Inc. Starts Experiments to Validate Its Own CAR-T Cell Therapy
Regen BioPharma, Inc. has announced the start of a series of phased experiments to advance its CAR-T cell de-differentiation approach through pre-clinical validation.
CAR-T cells are T cells (the body's lymphoid cells that kill tumors) that have been modified by expressing a chimeric antigen receptor (CAR) that is specific for the patient's tumor.
While CAR-T cells are effective in treating some lymphomas and leukemias, solid tumors such as the liver, breast, and colon are resistant to CAR-T therapies for a variety of reasons.
One cause is "T cell exhaustion," which occurs when the T cells that are initially recruited to the tumor to kill it lose their effectiveness. The company believes that NR2F6, a checkpoint that inhibits T cell activity, is a key player in the phenomenon of T Cell exhaustion. Inhibiting NR2F6 should keep these T cells from becoming dysfunctional.
To validate this approach, the Company has commissioned ProMab Biotechnologies, Inc. of Richmond, California to conduct a series of experiments using the Company's proprietary shRNA NR2F6-inhibiting technology.
"We are extremely excited to be using our cutting-edge genetic approach to create long-lasting CAR-T cells," says David Koos, Chairman and CEO of the Company.
"By partnering with a well-qualified organization such as ProMab Biotechnologies, Inc., we expect to quickly move this program forward to the clinic."
Note: Content may be edited for style and length.
Source
